• Product nameAnti-MEK1 antibody
    See all MEK1 primary antibodies
  • Description
    Rabbit polyclonal to MEK1
  • SpecificityThis antibody detects endogenous levels of total MEK1 protein.
  • Tested applicationsSuitable for: WB, ELISA, IHC-Pmore details
  • Species reactivity
    Reacts with: Human
    Predicted to work with: Mouse, Rat
  • Immunogen

    The antiserum was produced against synthesized non phosphopeptide derived from human MEK1 around the phosphorylation site of serine 221.

  • Positive control
    • WB: Human breast carcinoma tissue IHC-P: Jurkat cell extracts


Associated products


Our Abpromise guarantee covers the use of ab47422 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/500 - 1/1000. Detects a band of approximately 43 kDa (predicted molecular weight: 43 kDa).
ELISA 1/20000.
IHC-P Use at an assay dependent concentration.


  • FunctionCatalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP kinases. Activates ERK1 and ERK2 MAP kinases.
  • Tissue specificityWidely expressed, with extremely low levels in brain.
  • Involvement in diseaseDefects in MAP2K1 are a cause of cardiofaciocutaneous syndrome (CFC syndrome) [MIM:115150]; also known as cardio-facio-cutaneous syndrome. CFC syndrome is characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. The inheritance of CFC syndrome is autosomal dominant.
  • Sequence similaritiesBelongs to the protein kinase superfamily. STE Ser/Thr protein kinase family. MAP kinase kinase subfamily.
    Contains 1 protein kinase domain.
  • Post-translational
    Phosphorylation on Ser/Thr by MAP kinase kinase kinases (RAF or MEKK1) regulates positively the kinase activity.
    Acetylation by Yersinia yopJ prevents phosphorylation and activation, thus blocking the MAPK signaling pathway.
  • Information by UniProt
  • Database links
  • Alternative names
    • Dual specificity mitogen activated protein kinase kinase 1 antibody
    • Dual specificity mitogen-activated protein kinase kinase 1 antibody
    • ERK activator kinase 1 antibody
    • MAP kinase kinase 1 antibody
    • MAP kinase/Erk kinase 1 antibody
    • MAP2K1 antibody
    • MAPK/ERK kinase 1 antibody
    • MAPKK 1 antibody
    • MAPKK1 antibody
    • MEK 1 antibody
    • Mek1 antibody
    • MEKK1 antibody
    • Mitogen activated protein kinase kinase 1 antibody
    • MKK 1 antibody
    • MKK1 antibody
    • MP2K1_HUMAN antibody
    • PRKMK1 antibody
    • Protein kinase mitogen activated kinase 1 (MAP kinase kinase 1) antibody
    • Protein kinase mitogen activated, kinase 1 antibody
    see all

Anti-MEK1 antibody images

  • Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue in the presence (right) and absence (left) of synthetic peptide, using ab47422 at 1/50 dilution.
  • All lanes : Anti-MEK1 antibody (ab47422) at 1/500 dilution

    Lane 1 : UV treated Jurkat cell extracts
    Lane 2 : UV treated Jurkat cell extracts with synthetic peptide

    Predicted band size : 43 kDa
    Observed band size : 43 kDa

References for Anti-MEK1 antibody (ab47422)

This product has been referenced in:
  • Hirata H  et al. MicroRNA-1826 targets VEGFC, beta-catenin (CTNNB1) and MEK1 (MAP2K1) in human bladder cancer. Carcinogenesis 33:41-8 (2012). IHC-P ; Human . Read more (PubMed: 22049531) »
  • Hirata H  et al. MicroRNA-1826 directly targets beta-catenin (CTNNB1) and MEK1 (MAP2K1) in VHL-inactivated renal cancer. Carcinogenesis 33:501-8 (2012). IHC-P ; Human . Read more (PubMed: 22180573) »

See all 2 Publications for this product

Product Wall

There are currently no Abreviews or Questions for ab47422.
Please use the links above to contact us or submit feedback about this product.